Weekly Insulin Injections for Type 1 and Type 2 Diabetes Management
Key Findings from Recent Studies on Insulin
A new class of insulin, efsitora alfa, shows promise in managing both type 1 and type 2 diabetes effectively with fewer injections.
Study Details
- The trials presented at the European Association for the Study of Diabetes confirm weekly efsitora works comparably to daily insulin.
- In the trial with 928 individuals with type 2 diabetes, efsitora managed blood sugar levels on par with the long-acting degludec.
- The trial involving 623 participants with type 1 diabetes also demonstrated similar efficacy.
Potential Benefits for Diabetes Management
The introduction of weekly insulin injections could allow individuals managing type 1 diabetes and type 2 diabetes to have an easier regimen. This reduction in daily injection burden may encourage more people to initiate insulin therapy, promoting better health outcomes.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.